Trial Profile
A Randomized, Double Blind, Placebo Controlled Pilot Trial of Rituximab for Non-splenectomised Adults With Acute Immune Thrombocytopenic Purpura Receiving Standard Treatment (R-ITP)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Idiopathic thrombocytopenic purpura
- Focus Adverse reactions; Therapeutic Use
- 16 Apr 2014 New trial record
- 30 May 2012
- 21 Jul 2010